Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
Summit reported Q1 cash and short-term investments of $598.7 million, down from $713.4 million at year-end, with a GAAP net loss of $189.4 million driven by a $61.7 million increase in stock-based compensation and higher clinical trial costs. Operationally, the company highlighted that overall survival data from the Phase III HARMONi-6 study will be presented at the ASCO 2026 Plenary Session, a significant venue for high-impact oncology data.
Key figures
- Guidance
- HARMONi-3 squamous final PFS data expected second half 2026; HARMONi-3 non-squamous PFS data expected first half 2027
- Pdufa Date
- November 14, 2026
- Gaap Net Loss
- $189.4 million
- Cash Position
- $598.7 million
- Asco Presentation Date
- May 31, 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.